ENTPD3 and melanoma: As would be expected, high EVPL expression implied a suboptimal response to nivolumab and pembrolizumab in melanoma (Figure 5E), while gastric cancer patients with high ENTPD3 expression responded visibly better to pembrolizumab (Figure 5F).